Neurocrine Biosciences (NBIX) Gross Profit Growth (1y) (2018 - 2026)
Neurocrine Biosciences (NBIX) Gross Profit Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 2.43% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -8.36% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -5.56% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -3.83% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 9.27% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 38.19% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 11.92% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 16.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.19% |
| Mar 31, 2026 | 42.12% |
| Dec 31, 2025 | 27.41% |
| Sep 30, 2025 | 27.16% |
| Jun 30, 2025 | 16.39% |
| Mar 31, 2025 | 10.95% |
| Dec 31, 2024 | 22.04% |
| Sep 30, 2024 | 25.94% |
| Jun 30, 2024 | 31.69% |
| Mar 31, 2024 | 23.28% |
| Dec 31, 2023 | 25.33% |
| Sep 30, 2023 | 27.71% |
| Jun 30, 2023 | 2,802.63% |
| Mar 31, 2023 | 34.61% |
| Dec 31, 2022 | 31.31% |
| Sep 30, 2022 | 30.84% |
| Jun 30, 2022 | -94.68% |
| Mar 31, 2022 | 30.94% |
| Dec 31, 2021 | 25.67% |
| Sep 30, 2021 | 14.07% |